Nevertheless, these studies have suggested that among dMMR/MSI, HSP110 T17 deletion size could be associated with sensitivity to adjuvant 5FU, a finding suggesting that non-metastatic dMMR/MSI CRC could have different levels of chemoresistance to 5FU due to HSP110 T17 deletion. This evidence concerns the gene HSPH1 and colorectal carcinoma.